135
Views
5
CrossRef citations to date
0
Altmetric
Short Report

Safety and durability of PEG-J: a single-centre experience

ORCID Icon, ORCID Icon, ORCID Icon, , & ORCID Icon
Pages 1377-1380 | Received 16 Jun 2020, Accepted 21 Sep 2020, Published online: 06 Oct 2020

References

  • Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson’s disease. Curr Med Res Opin. 2011;27:907–919.
  • Dam-Larsen S, Darkahi B, Glad A, et al. Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson’s disease in the Nordic region. Scand J Gastroenterol. 2015;50:1500–1507.
  • Toh Yoon EW, Yoneda K, Nakamura S, et al. Percutaneous endoscopic transgastric jejunostomy (PEG-J): a retrospective analysis on its utility in maintaining enteral nutrition after unsuccessful gastric feeding. BMJ Open Gastroenterol. 2016;3:e000098.
  • Strijbos D, Keszthelyi D, Smeets FGM, et al. Therapeutic strategies in gastroparesis: results of stepwise approach with diet and prokinetics, Gastric Rest, and PEG-J: a retrospective analysis. Neurogastroenterol Motil. 2019;31:e13588.
  • Fonseca J, Santos CA. Percutaneous endoscopic gastrostomy with jejunal extension plus percutaneous endoscopic gastrostomy (PEG-j plus PEG) in patients with gastric/duodenal cancer outlet obstruction. Arq Gastroenterol. 2015;52:72–75.
  • Olanow CW, Kieburtz K, Odin P, et al. LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–149.
  • Antonini A, Poewe W, Chaudhuri KR, et al. GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20.
  • Devos D, French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009;24:993–1000.
  • Ridtitid W, Lehman GA, Watkins JL, et al. Short- and long-term outcomes from percutaneous endoscopic gastrostomy with jejunal extension. Surg Endosc. 2017;31:2901–2909.
  • DeLegge MH, Patrick P, Gibbs R. Percutaneous endoscopic gastrojejunostomy with a tapered tip, nonweighted jejunal feeding tube: improved placement success. Am J Gastroenterol. 1996;91:1130–1134.
  • DiSario J, Foutch P, Sanowski R. Poor results with percutaneous endoscopic jejunostomy. Gastrointest Endosc. 1990;36:257–260.
  • Epstein M, Johnson DA, Hawes R, et al. Long-term PEG-J tube safety in patients with advanced Parkinson’s disease. Clin Transl Gastroenterol. 2016;7:e159.
  • Gore DC, DeLegge M, Gervin A, et al. Surgically placed gastro-jejunostomy tubes have fewer complications compared to feeding jejunostomy tubes. J Am Coll Nutr. 1996;15:144–146.
  • Zulli C, Sica M, De Micco R, et al. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson’s disease: a preliminary study. Eur Rev Med Pharmacol Sci. 2016;20:2413–2417.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.